TCRR
TCR2 Therapeutics, Inc.
$1.5
Earnings Summary
Net Profits | $-13.81Mn |
Highlights
TCR2 Therapeutics, Inc.’s net profit fell -116.12% since last year same period to $-13.81Mn in the Q3 2019. On a quarterly growth basis, TCR2 Therapeutics, Inc. has generated -24.79% fall in its net profits since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the TCR2 Therapeutics, Inc. post its latest quarter earnings
EPS Estimate Current Quarter | -0.8 |
EPS Estimate Current Year | -0.8 |
Highlights
TCR2 Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.8 - a -6.08% fall from last quarter’s estimates.
TCR2 Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.8.
Key Ratios
Key ratios of the TCR2 Therapeutics, Inc. post its Q4 2022 earnings
Return on Assets (ROA) | -0.23 |
Return on Equity (ROE) | -0.47 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. TCR2 Therapeutics, Inc.’s return on assets (ROA) stands at -0.23.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. TCR2 Therapeutics, Inc.’s return on equity (ROE) stands at -0.47.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-03-22 | -0.75 | -0.72 | 4% |
2021-08-05 | -0.59 | -0.64 | -8.47% |
2021-11-10 | -0.65 | -0.69 | -6.15% |
2021-05-13 | -0.53 | -0.58 | -9.43% |
Company Information
TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2's proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company's lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).
Organisation | TCR2 Therapeutics, Inc. |
Headquarters | 100 Binney Street, Cambridge, MA, United States, 02142 |
Employees | 105 |
Industry | Pharmaceuticals: Major |
CEO | Garry Menzel |
